{"drugs":["Lopressor","Metoprolol Tartrate"],"mono":[{"id":"373270-s-0","title":"Generic Names","mono":"Metoprolol Tartrate"},{"id":"373270-s-1","title":"Dosing and Indications","sub":[{"id":"373270-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Acute myocardial infarction:<\/b> early treatment, initial, 3 IV boluses of 5 mg each at 2-minute intervals upon patient presentation; 15 minutes after full IV dose (15 mg), initiate 50 mg ORALLY every 6 hours for 48 hours; if unable to tolerate the full IV dose, initiate 25 to 50 mg ORALLY every 6 hours for 48 hours<\/li><li><b>Acute myocardial infarction:<\/b> maintenance or late treatment, 100 mg ORALLY twice daily for 3 months to 3 years<\/li><li><b>Angina:<\/b> initial, 100 mg ORALLY daily administered in 2 divided doses; may increase dose gradually at weekly intervals<\/li><li><b>Angina:<\/b> maintenance, 100 to 400 mg ORALLY daily administered in divided doses<\/li><li><b>Atrial fibrillation, Postoperative; Prophylaxis - Operation on heart:<\/b> 1 to 3 mg\/hr IV infusion for 48 hours; doses were determined according to heart rate (HR): HR 60 to 70 beats per minute (bpm), metoprolol IV 1 mg\/hr; HR 70 to 80 bpm, IV 2 mg\/hr; HR greater than 80 bpm, IV 3 mg\/hr (study dosing)<\/li><li><b>Cardiac dysrhythmia:<\/b> 25 to 100 mg ORALLY daily<\/li><li><b>Cardiac dysrhythmia:<\/b> 2 to 20 mg IV<\/li><li><b>Congestive heart failure:<\/b> initial, 6.25 mg ORALLY twice daily; titration, increase dose gradually over 4 to 6 weeks to target dose of 50 mg ORALLY twice daily<\/li><li><b>Hypertension:<\/b> initial, 100 mg ORALLY once daily or in 2 divided doses; range 100 to 450 mg per day; titrate at weekly or longer intervals until optimum blood pressure achieved; maximum effect of dose is evident after 1 week<\/li><li><b>Migraine; Prophylaxis:<\/b> 50 to 200 mg ORALLY daily<\/li><li><b>Thyrotoxicosis:<\/b> 25 to 50 mg ORALLY 4 times daily (guideline dosing)<\/li><\/ul>"},{"id":"373270-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established in children<\/li><li><b>Hypertension:<\/b> initial, 1 to 2 mg\/kg\/day ORALLY in 2 divided doses; MAX 6 mg\/kg\/day ORALLY up to 200 mg\/day in 2 divided doses<\/li><\/ul>"},{"id":"373270-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> no dosage adjustment necessary<\/li><li><b>liver disease:<\/b> initiate at low doses; cautiously and slowly increase dose if necessary<\/li><li><b>geriatric:<\/b> use low initial starting doses<\/li><\/ul>"},{"id":"373270-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acute myocardial infarction<\/li><li>Angina<\/li><li>Hypertension<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Aggressive behavior<\/li><li>Anxiety<\/li><li>Atrial fibrillation, Postoperative; Prophylaxis - Operation on heart<\/li><li>Cardiac dysrhythmia<\/li><li>Congenital long QT syndrome<\/li><li>Congestive heart failure<\/li><li>Glaucoma<\/li><li>Injection site pain - Propofol adverse reaction<\/li><li>Ischemic heart disease, acute; Prophylaxis<\/li><li>Migraine; Prophylaxis<\/li><li>Thyrotoxicosis<\/li><li>Tremor<\/li><\/ul>"}]},{"id":"373270-s-2","title":"Black Box Warning","mono":"<ul><li><b>Intravenous (Solution)<\/b><br\/>Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. The dosage should be gradually reduced over a period of 1 to 2 weeks and the patient should be carefully monitored when discontinuing chronic therapy. If angina markedly worsens or acute coronary insufficiency develops, metoprolol tartrate administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue metoprolol tartrate therapy abruptly even in patients treated only for hypertension.<br\/><\/li><li><b>Oral (Tablet)<\/b><br\/>Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. The dosage should be gradually reduced over a period of 1 to 2 weeks and the patient should be carefully monitored when discontinuing chronic therapy. If angina markedly worsens or acute coronary insufficiency develops, metoprolol tartrate administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue metoprolol tartrate therapy abruptly even in patients treated only for hypertension.<br\/><\/li><\/ul>"},{"id":"373270-s-3","title":"Contraindications\/Warnings","sub":[{"id":"373270-s-3-9","title":"Contraindications","mono":"<ul><li>bradycardia, sinus (patients with hypertension and angina)<\/li><li>cardiac failure, overt (patients with hypertension and angina)<\/li><li>cardiac failure, moderate to severe (patients with myocardial infarction)<\/li><li>cardiogenic shock (patients with hypertension and angina)<\/li><li>heart block, second and third degree<\/li><li>heart block, first degree (PR interval 0.24 second or greater) (patients with myocardial infarction)<\/li><li>heart rate less than 45 beats\/minute (patients with myocardial infarction)<\/li><li>hypersensitivity to metoprolol, related derivatives, other beta-blockers, or any component of the product<\/li><li>peripheral arterial circulatory disorders, severe (patients with hypertension and angina)<\/li><li>sick-sinus syndrome (patients with hypertension and angina)<\/li><li>systolic blood pressure less than 100 mmHg (patients with myocardial infarction)<\/li><\/ul>"},{"id":"373270-s-3-10","title":"Precautions","mono":"<ul><li>abrupt withdrawal; severe exacerbation of angina pectoris, myocardial infarction, and ventricular arrhythmia have been reported in patients with coronary artery disease; reduce dose gradually; monitoring recommended<\/li><li>abrupt withdrawal, in thyrotoxicosis; may precipitate a thyroid storm<\/li><li>anaphylactic reactions to variety of allergens, history of; may be more reactive to repeated challenge<\/li><li>anesthesia and major surgery; impairs ability of heart to respond to reflex adrenergic stimuli; however, chronic beta-blocker therapy should NOT routinely be withdrawn<\/li><li>atrioventricular conduction, slowing may lead to heart block; may require medical management and discontinuation of therapy<\/li><li>bradycardia, including sinus pause, heart block, and cardiac arrest have been reported, increased risk in patients with first-degree atrioventricular block, sinus node dysfunction, or conduction disorders; dose reduction or discontinuation may be necessary; monitoring recommended<\/li><li>bronchospastic disease; generally should not receive beta-blockers; dose adjustment required; bronchodilator rescue availability is necessary<\/li><li>diabetes mellitus; possibility of masked symptoms of hypoglycemia, such as tachycardia<\/li><li>dipyridamole testing; withdraw beta-blocker therapy prior to; monitoring recommended<\/li><li>heart failure; may cause myocardial contractility depression and precipitate heart failure and cardiogenic shock; dose reduction or drug discontinuation may be necessary<\/li><li>hepatic impairment<\/li><li>hypotension (systolic blood pressure of 90 mmHg or less) may occur; medical management and metoprolol discontinuation recommended<\/li><li>pheochromocytoma; associated with paradoxical increase in blood pressure without first administering with an alpha-blocker<\/li><li>thyrotoxicosis; may mask clinical signs of hyperthyroidism, such as tachycardia<\/li><li>withdrawal of concomitant clonidine therapy; metoprolol may exaggerate clonidine withdrawal syndrome and increase risk of rebound hypertension; metoprolol should be discontinued several days before clonidine is withdrawn<\/li><\/ul>"},{"id":"373270-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Metoprolol: C (FDA)<\/li><li>Metoprolol: C (AUS)<\/li><\/ul>"},{"id":"373270-s-3-12","title":"Breast Feeding","mono":"<ul><li>Metoprolol: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Metoprolol: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},{"id":"373270-s-4","title":"Drug Interactions","sub":{"1":{"id":"373270-s-4-14","title":"Major","mono":"<ul><li>Albuterol (theoretical)<\/li><li>Amiodarone (established)<\/li><li>Arformoterol (theoretical)<\/li><li>Bambuterol (theoretical)<\/li><li>Clenbuterol (theoretical)<\/li><li>Clonidine (theoretical)<\/li><li>Colterol (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Diltiazem (probable)<\/li><li>Dronedarone (probable)<\/li><li>Fenoldopam (theoretical)<\/li><li>Fenoterol (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Hexoprenaline (theoretical)<\/li><li>Indacaterol (theoretical)<\/li><li>Isoetharine (theoretical)<\/li><li>Lacosamide (theoretical)<\/li><li>Levalbuterol (theoretical)<\/li><li>Lidocaine (probable)<\/li><li>Metaproterenol (theoretical)<\/li><li>Olodaterol (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pirbuterol (theoretical)<\/li><li>Procaterol (theoretical)<\/li><li>Reproterol (theoretical)<\/li><li>Ritodrine (theoretical)<\/li><li>Rivastigmine (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Terbutaline (theoretical)<\/li><li>Tretoquinol (theoretical)<\/li><li>Tulobuterol (theoretical)<\/li><li>Verapamil (probable)<\/li><li>Vilanterol (theoretical)<\/li><\/ul>"},"2":{"id":"373270-s-4-15","title":"Moderate","mono":"<ul><li>Acarbose (probable)<\/li><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Acetyldigoxin (probable)<\/li><li>Albiglutide (probable)<\/li><li>Alfuzosin (probable)<\/li><li>Alogliptin (probable)<\/li><li>Amlodipine (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Arbutamine (probable)<\/li><li>Aspirin (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Bunazosin (probable)<\/li><li>Canagliflozin (probable)<\/li><li>Celecoxib (probable)<\/li><li>Chlorpropamide (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Citalopram (probable)<\/li><li>Clonixin (probable)<\/li><li>Dapagliflozin (probable)<\/li><li>Deslanoside (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Digitoxin (probable)<\/li><li>Digoxin (probable)<\/li><li>Dipyrone (probable)<\/li><li>Doxazosin (probable)<\/li><li>Dulaglutide (probable)<\/li><li>Empagliflozin (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Exenatide (probable)<\/li><li>Felbinac (probable)<\/li><li>Felodipine (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Indomethacin (probable)<\/li><li>Insulin Aspart, Recombinant (probable)<\/li><li>Insulin Degludec (probable)<\/li><li>Insulin Detemir (probable)<\/li><li>Insulin Glargine, Recombinant (probable)<\/li><li>Insulin Glulisine (probable)<\/li><li>Insulin Human Inhaled (probable)<\/li><li>Insulin Human Isophane (NPH) (probable)<\/li><li>Insulin Human Regular (probable)<\/li><li>Insulin Lispro, Recombinant (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Lacidipine (probable)<\/li><li>Lercanidipine (probable)<\/li><li>Linagliptin (probable)<\/li><li>Liraglutide (probable)<\/li><li>Lixisenatide (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Manidipine (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Metformin (probable)<\/li><li>Metildigoxin (probable)<\/li><li>Mibefradil (probable)<\/li><li>Miglitol (probable)<\/li><li>Mirabegron (established)<\/li><li>Morniflumate (probable)<\/li><li>Moxisylyte (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nateglinide (probable)<\/li><li>Nepafenac (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nifedipine (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimesulide (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Parecoxib (probable)<\/li><li>Phenelzine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenoxybenzamine (probable)<\/li><li>Phentolamine (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Pioglitazone (probable)<\/li><li>Piroxicam (probable)<\/li><li>Pramlintide (probable)<\/li><li>Pranidipine (probable)<\/li><li>Prazosin (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propoxyphene (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Repaglinide (probable)<\/li><li>Rifampin (probable)<\/li><li>Rifapentine (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Rosiglitazone (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Saxagliptin (probable)<\/li><li>Sitagliptin (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>St John's Wort (probable)<\/li><li>Sulindac (probable)<\/li><li>Tamsulosin (probable)<\/li><li>Telithromycin (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Terazosin (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Trimazosin (probable)<\/li><li>Urapidil (probable)<\/li><li>Valdecoxib (probable)<\/li><li>Venlafaxine (established)<\/li><li>Vildagliptin (probable)<\/li><\/ul>"}}},{"id":"373270-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Bradyarrhythmia (3%-16%), Heart block (5%), Heart failure (27%), Hypotension (1%-27%)<\/li><li><b>Dermatologic:<\/b>Pruritus (5%), Rash (5%)<\/li><li><b>Gastrointestinal:<\/b>Constipation (1%), Diarrhea (5%), Indigestion (1%), Nausea (1%)<\/li><li><b>Neurologic:<\/b>Dizziness (10%), Fatigue (10%), Headache<\/li><li><b>Psychiatric:<\/b>Depression (5%)<\/li><li><b>Respiratory:<\/b>Dyspnea (1%-3%), Wheezing (1%)<\/li><\/ul><b>Serious<\/b><br\/><b>Respiratory:<\/b>Bronchospasm (1%)<br\/>"},{"id":"373270-s-6","title":"Drug Name Info","sub":{"0":{"id":"373270-s-6-17","title":"US Trade Names","mono":"Lopressor<br\/>"},"2":{"id":"373270-s-6-19","title":"Class","mono":"<ul><li>Beta-Adrenergic Blocker, Cardioselective<\/li><li>Cardiovascular Agent<\/li><\/ul>"},"3":{"id":"373270-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"373270-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"373270-s-7","title":"Mechanism Of Action","mono":"Metoprolol tartrate is a beta-adrenergic blocker with selective activity on beta-1 adrenoreceptors located mainly in cardiac muscles. At higher doses, it may inhibit beta-2 adrenoreceptors of bronchial and vascular smooth muscles. Possible mechanisms of antihypertensive effects of metoprolol include: competitive antagonism of catecholamines at peripheral and cardiac adrenergic receptors (resulting in decreased cardiac output), a central effect leading to reduced sympathetic outflow, and suppression of renin activity. Metoprolol is beneficial in angina pectoris treatment by blocking catecholamine-induced increases in heart rate, velocity and extent of myocardial contractility, and blood pressure, resulting in reduced oxygen requirements of the heart. The mechanism of action of metoprolol in myocardial infarction is unknown.<br\/>"},{"id":"373270-s-8","title":"Pharmacokinetics","sub":[{"id":"373270-s-8-23","title":"Absorption","mono":"Bioavailability, Oral: approximately 50% <br\/>"},{"id":"373270-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding, albumin: about 10%<\/li><li>Vd: 3.2 to 5.6 L\/kg<\/li><\/ul>"},{"id":"373270-s-8-25","title":"Metabolism","mono":"<ul><li>Liver: main route<\/li><li>Substrate of CYP2D6.<\/li><\/ul>"},{"id":"373270-s-8-26","title":"Excretion","mono":"<ul><li>Renal: 95% (IV, 10% unchanged; oral, 5% unchanged)<\/li><li>Renal, poor CYP2D6 metabolizers: 95% (IV, 40% unchanged; oral, 30% unchanged)<\/li><\/ul>"},{"id":"373270-s-8-27","title":"Elimination Half Life","mono":"<ul><li>3 to 4 hours<\/li><li>Hepatic impairment; up to 7.2 hours<\/li><li>Poor CYP2D6 metabolizers: 7 to 9 hours<\/li><\/ul>"}]},{"id":"373270-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>take in standardized relation to meals, preferably with or immediately following meals; swallow tablet whole with a glass of water <br\/>"},{"id":"373270-s-10","title":"Monitoring","mono":"<ul><li>angina pectoris: reduced incidence of angina attacks and improved exercise tolerance indicates efficacy<\/li><li>hypertension: blood pressure; near end of dosing interval to confirm 24-hour hypertension control, especially with lower doses<\/li><li>myocardial infarction: blood pressure, heart rate, and ECG; during administration in early treatment<\/li><li>heart rate and rhythm; during therapy, especially in patients with first degree atrioventricular block, sinus node dysfunction, or conduction disorders<\/li><li>ischemic heart disease (ie, angina exacerbations or acute coronary insufficiency); while gradually discontinuing chronic therapy, especially in patients with coronary artery disease<\/li><\/ul>"},{"id":"373270-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Intravenous Solution: 1 MG\/ML<\/li><li>Oral Tablet: 25 MG, 50 MG, 100 MG<\/li><\/ul><\/li><li><b>Lopressor<\/b><br\/>Oral Tablet: 50 MG, 100 MG<br\/><\/li><\/ul>"},{"id":"373270-s-12","title":"Toxicology","sub":[{"id":"373270-s-12-31","title":"Clinical Effects","mono":"<b>BETA-BLOCKING AGENTS <\/b><br\/>USES: Used primarily to treat hypertension.  Also used as a treatment for akathisia, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, stable angina, tachydysrhythmias, thyrotoxicosis, congestive heart failure, congenital heart conditions, and for migraine headache prophylaxis and variceal hemorrhage prophylaxis. Bimatoprost\/timolol and travoprost\/timolol ophthalmic combinations are indicated for the reduction of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma. Refer to beta-blocking agents document for more information. PHARMACOLOGY: Inhibition\/competitive blockade of beta-adrenergic receptors. TOXICOLOGY: The toxicity of beta-blockers is an extension of their therapeutic effects. They cause bradycardia, heart-block and hypotension. Propranolol has sodium channel blocking properties and may cause ventricular dysrhythmias. EPIDEMIOLOGY: Poisoning is uncommon but can be very severe.  May occur via oral, intravenous or ophthalmic administration. MILD TO MODERATE POISONING: Decreased heart rate and hypotension. SEVERE POISONING: Atrioventricular blocks, intraventricular conduction delays, and congestive heart failure can occur with more severe poisoning. Coma and cardiopulmonary arrest can develop secondary to severe hypotension\/bradycardia.  Bronchospasm may develop, particularly in patients with asthma or COPD, and respiratory depression may develop in patients with severe hypotension.  Propranolol is highly lipid-soluble and may cross the blood brain barrier and cause seizures.  Propranolol may cause QRS widening resulting in ventricular dysrhythmias due to sodium channel blockade.  Renal failure and pulmonary edema may develop in patients with prolonged hypotension.  Hypoglycemia may develop in diabetics or those with decreased glycogen stores (eg, children, fasting, exercising); manifestations of hypoglycemia (tremor, tachycardia) may be masked by clinical effects of beta-blocker toxicity. OCULAR EXPOSURE: Ophthalmic preparations containing beta-blockers may cause systemic manifestations. ONSET: Symptoms usually occur within 6 hours, but can be as early as 20 minutes and may be delayed with sustained release products. ADVERSE EFFECTS: Hypotension, bradycardia, first-degree heart block, dizziness, fatigue, depression, pruritus, rash, diarrhea, dyspnea, bronchospasm, hypoglycemia, and seizures are among the adverse effects. Superficial punctate keratitis, corneal erosion, burning sensation, eyelid pruritus, eye dryness, eye pain, photophobia, eye discharge, visual disturbances, eyelid erythema, and blepharal pigmentation have been reported in up to 10% of patients receiving bimatoprost\/timolol ophthalmic solution. Eye pain, ocular discomfort, dry eye, and eye pruritus have been reported in up to 10% of patients receiving travoprost\/timolol maleate (polyquaternium-1-preserved).<br\/>"},{"id":"373270-s-12-32","title":"Treatment","mono":"<b>BETA-BLOCKING AGENTS <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Place patient on a cardiac monitor, give fluids for hypotension, and atropine for bradycardia. MANAGEMENT OF SEVERE TOXICITY: Perform early orotracheal intubation for airway protection if the patient has altered mental status. Initially manage hypotension with intravenous fluids (500 mL boluses up to 2L) and atropine for symptomatic bradycardia. Glucagon should be considered if the patient does not respond appropriately to intravenous fluids. Give catecholamines to those who do not respond to intravenous fluids and glucagon. No one catecholamine has been shown to be consistently effective; dopamine, norepinephrine and epinephrine may be considered. High doses may be required. If catecholamines are required despite glucagon and intravenous fluids, high-dose insulin euglycemia should be considered. Catecholamines should be titrated down when high-dose insulin euglycemia therapy starts to take effect. Intravenous lipid emulsion should be considered in patients with refractory hypotension. Other non-pharmacological therapies include: cardiac pacing, placement of an intraaortic balloon pump, cardiopulmonary bypass, and extracorporeal membrane oxygenation (ECMO). Seizures (rarely progress to status epilepticus) may require aggressive use of benzodiazepines (e.g. 1 to 2 mg lorazepam IV and increase as needed) and\/or propofol. Monitor for dysrhythmias and treat accordingly.<\/li><li>Decontamination: PREHOSPITAL: Activated charcoal if recent, substantial ingestion, and patient able to protect airway. HOSPITAL: Activated charcoal if recent, substantial ingestion, and patient able to protect airway. After airway protection consider gastric lavage in recent, large ingestion, or whole bowel irrigation.<\/li><li>Airway management: Perform early in a patient with severe intoxication (depressed mental status, seizures, dysrhythmias).<\/li><li>Hypotensive episode: Initially manage hypotension with intravenous fluids (500 mL boluses up to 2L) and atropine for symptomatic bradycardia.<\/li><li>Antidote: GLUCAGON: Patients who do not respond to intravenous fluids (500 mL boluses up to 2L) and atropine should be treated with glucagon.  Initial dosing is 5 to 15 mg by slow IV push followed by an infusion rate of 5 to 15 mg\/hour. Glucagon may also induce nausea\/vomiting, as well as elevate blood glucose.<\/li><li>Insulin: High-dose insulin euglycemia (HIS) may be considered in patients who do not respond adequately to fluids and catecholamines. HIS is another potential therapy with some positive animal data and case-based human evidence.  Administer a bolus of 1 unit\/kilogram of insulin followed by an infusion of 0.1 to 1 units\/kilogram\/hour, titrated to a systolic blood pressure of greater than 90 to 100 mmHg (bradycardia may or may not respond). Reassess every 30 minutes to titrate insulin infusion. High-dose insulin euglycemia therapy may allow the practitioner to decrease the dose of catecholamines and avoid the adverse effects of prolonged high dose catecholamines. Before, during, and after the therapy, monitor for hypoglycemia and hypokalemia. Administer dextrose bolus to patients with an initial blood glucose of less than 250 mg\/dL (Adult: 25 to 50 mL dextrose 50%; Children: 0.25 g\/kg dextrose 25%). Begin a dextrose infusion of 0.5 g\/kg\/hour in all patients. Monitor blood glucose every 15 to 30 minutes until consistently 100 to 200 mg\/dL for 4 hours, then monitor every hour. Titrate dextrose infusion to maintain blood glucose in the range of 100 to 200 mg\/dL. As the patient improves, insulin resistance abates and dextrose requirements will increase. Supplemental dextrose will be needed for at least several hours after the insulin infusion is discontinued. Administer supplemental potassium initially if patient is hypokalemic (serum potassium less than 2.5 mEq\/L). Monitor serum potassium every 4 hours and supplement as needed to maintain potassium of 2.5 to 2.8 mEq\/L.<\/li><li>Fat Emulsion: Another potential pharmacological treatment is with lipid emulsion therapy, though at this point in time, there is only animal data supporting its use in beta-blocker toxicity; in theory it may be effective for lipid soluble beta blockers such as propranolol.  The dose of 20% lipid emulsion is 1.5 mL\/kg over 1 minute followed immediately with an infusion at a rate of 0.25 mL\/kg\/min, and to repeat the bolus dosing every 3 to 5 minutes up to 3 mL\/kg total dose until circulation is restored.  If BP declines, increase the infusion rate to 0.5 mL\/kg\/min. A maximum dose of 8 mL\/kg is recommended.  For example, the resuscitation of an adult weighing 70 kg is equivalent to taking a 500 mL bag of 20% lipid emulsion and drawing up 50 mL twice and giving it IV push, and then attaching the infusion bag to an IV and running it in over 15 minutes.<\/li><li>Inamrinone: A phosphodiesterase inhibitor which also has theoretical benefit via decreasing breakdown of myocardial cAMP.  The dosing is 1 mg\/kg bolus then 3 to 6 mcg\/kg\/minute.  It is very rarely used because, although it increases inotropy, it may induce peripheral vasodilation and is difficult to titrate due to a relatively long half-life.<\/li><li>Calcium: Calcium chloride has been effective for propranolol, concurrent administration of atenolol and verapamil, and a mixed metoprolol\/verapamil overdose that were refractory to conventional therapy. Administer calcium chloride 0.2 mL\/kg or calcium gluconate 0.6 mL\/kg intravenously.<\/li><li>Bradycardia: Atropine, glucagon (50-150 mcg\/kg bolus followed by an infusion 1-5 mg\/hr), and pacemaker.<\/li><li>Seizure: Seizures (may rarely progress to status epilepticus) may require aggressive use of benzodiazepines (e.g. 1-2 mg lorazepam IV and increase as needed) and\/or propofol.<\/li><li>Conduction disorder of the heart: QRS widening or ventricular tachycardia may respond to sodium bicarbonate.  A reasonable starting dose is 1 to 2 mEq\/kg bolus, repeat as needed; endpoints include resolution of dysrhythmias, narrowing of QRS complex and blood pH 7.45 to 7.55.  Use lidocaine (1 mg\/kg intravenous bolus followed by 20 to 50 mcg\/kg\/min intravenous infusion) if sodium bicarbonate is not successful.<\/li><li>Monitoring of patient: Monitor vital signs and mental status. Specific beta-blocker plasma levels are not clinically useful or readily available. No specific lab work is needed in most patients. Obtain an ECG and institute continuous cardiac monitoring.  Monitor serum electrolytes and renal function in patients with significant hypotension or dysrhythmias. Monitor blood glucose in children, diabetics, and patients with altered mentation.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion may be useful for beta blockers with small volumes of distribution such as atenolol, sotalol and nadolol; experience is limited to a few case reports.  Hemodialysis and hemoperfusion are not useful  for beta-blockers with large volumes of distribution.<\/li><li>Patient disposition: HOME CRITERIA: Healthy, asymptomatic patients with an inadvertent ingestion of less than or equal to a maximum daily dose for age may be monitored at home. OBSERVATION CRITERIA: Patients with underlying cardiovascular or respiratory disease, those ingesting more than a maximum daily dose, those who co-ingest calcium channel blockers, and those with deliberate overdose of beta-blocking agents should have a baseline ECG and be monitored for a minimum of 6 hours. Patients who develop signs of toxicity during observation should be admitted, while those who are asymptomatic after 6 hours may be discharged, following psychiatric consultation if indicated. Longer observation (at least 8 hours) is required for patients ingesting sustained release products. ADMISSION CRITERIA: Symptomatic patients with cardiovascular symptoms (ie, hypotension, bradycardia) or central nervous system toxicity (ie, somnolence, seizures, coma) should be admitted to an intensive care setting for further observation\/treatment and monitored until they are asymptomatic for a prolonged period (several hours)  without therapy.  CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients with toxicity (hypotension, seizures, dysrhythmias), or in whom the diagnosis is not clear.<\/li><\/ul>"},{"id":"373270-s-12-33","title":"Range of Toxicity","mono":"<b>BETA-BLOCKING AGENTS<\/b><br\/>TOXICITY: The toxic dose is variable depending on the particular agent.  The following ingestions should be considered potentially toxic: ACEBUTOLOL: ADULT: greater than 600 mg; CHILD: greater than 12 mg\/kg. ATENOLOL: ADULT: greater than 200 mg; CHILD: greater than 2 mg\/kg. CARVEDILOL: ADULT: greater than 50 mg; CHILD: greater than 0.5 mg\/kg. LABETALOL: ADULT: greater than 400 mg; CHILD: greater than 20 mg\/kg. METOPROLOL: ADULT: greater than 450 mg IR or greater than 400 mg SR; CHILD: greater than 2.5 mg\/kg IR or greater than 5 mg\/kg SR. NADOLOL: ADULT: greater than 320 mg; CHILD: greater than 2.5 mg\/kg. PROPRANOLOL: ADULT: greater than 240 mg; CHILD: greater than 4 mg\/kg IR, or greater than 5 mg\/kg SR. TIMOLOL: ADULT: greater than 30 mg (tablets); CHILD: any amount.<br\/>"}]},{"id":"373270-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring coordination until drug effects are realized, as drug may cause dizziness.<\/li><li>This drug may cause diarrhea, depression, or fatigue.<\/li><li>Advise patient to report signs\/symptoms of cardiac failure. This drug may precipitate or exacerbate cardiac failure in CHF patients.<\/li><li>Tell patient to report signs\/symptoms of arrhythmias or hypotension.<\/li><li>Drug may mask symptoms of hypoglycemia. Advise diabetics to report difficulties with glycemic control.<\/li><li>Patient should take extended-release tablet with or immediately following meals.<\/li><li>Advise patient against sudden interruption or discontinuation of drug, as this may exacerbate angina or cause myocardial infarction. Sudden discontinuation by patients with thyrotoxicosis may precipitate thyroid storm.<\/li><li>Instruct patient to take a missed dose as soon as possible, but if next dose is in less than 4 h, skip the missed dose.<\/li><\/ul>"}]}